Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the first half of 2024 for a new iteration of its bronchodilator Ventolin (salbutamol). This version utilizes a low-carbon propellant, which could potentially reduce the greenhouse gas emissions from the associated metered dose inhaler (MDI) by approximately 90%. The company reports that 35 million patients worldwide rely on the product, which constitutes 49% of Gilead’s total carbon footprint.
Support from Clinical Data and Anticipated Regulatory Filings
The decision to proceed with the study is bolstered by clinical data from earlier trials. Gilead anticipates filing for regulatory approval in 2025, aligning with the company’s commitment to sustainable healthcare solutions.- Flcube.com
